Visit Aggrego Advances hub to learn more about the late breaking developments from the POSEIDON trial 

Thursday
February
02
Top Stories
Proteomics Biomarker Discovery for Individualized Prevention of Familial Pancreatic Cancer Using Statistical Learning

In the simulation study, model-based gradient boosting showed a more accurate prediction performance in the small, unbalanced, and high-dimensional datasets than adaptive lasso and could identify m

PLOS ONE
21h ago
Preferences, Barriers, and Facilitators Regarding Virtual Pelvic Health Care in Individuals With Gynaecological Cancers: Protocol for a Patient-Oriented, Mixed-Methods Study

Given that barriers such as time, travel, and costs are known to limit access to physiotherapy services, a virtual pelvic health physiotherapy programme may help to facilitate access. 

BMJ Open
21h ago
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma

The second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but statistically nonsignificant improvement with the addition of first-line atezolizumab to vemur

The ASCO Post
21h ago
Aggregation Tests Identify New Gene Associations With Breast Cancer in Populations With Diverse Ancestry

Using extended gene-based aggregation tests including coding and regulatory variation, we report identification of plausible target genes for previously identified single-marker associations with B

Genome Medicine
1d ago

Spotlight

Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy. 

Radio
Lung Cancer
Aggrego Oncology - 3/24/22
Aggrego Oncology
10m ago
Aggrego Pulse - 10/07/21
Aggrego Oncology
1y ago